This study reveals a novel role for KLF4 PARylation in DNA damage response in cancer, and reports a synergy between targeting KLF4 and PARP1 in the treatment of triple negative breast cancer (TNBC). The gene discussed is KLF4; the disease is triple-negative breast carcinoma.